The group's principal activity is to research and develop therapeutic products for the treatment of cancer and cancer related disorders. the group's product erbitux(tm) is a therapeutic monoclonal antibody that inhibits stimulation of epidermal growth factor (egf) receptor upon which certain solid tumors depend in order to grow. the group also develops the inhibitors of angiogenesis, which can be used to treat various kinds of cancer and other diseases. license fees accounted for 96% of 2001 revenues and research and development funding and royalties, 4%.